Data from a new mouse model may help advance therapeutic development in celiac disease, including improved TG2 inhibitors and ...
The financing was led by Lapam Capital, with participation from Frees Fund and Riverhead Capital.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback